NCT05774509进行中（未招募）1 期
Treatment of Non-ischemic Dilated Cardiomyopathies by Intravenous Infusions of the Extracellular Vesicle-Enriched Secretome of Cardiovascular Progenitor Cells
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Serious Adverse Events
研究概览
简要总结
The goal of this clinical trial is to assess the safety and efficacy of three intravenous injections of the extracellulat vesicle-enriched secretome of cardiovascular progenitor cells in severely symptomatic patients with drug-refractory left ventricular (LV) dysfunction secondary to non-ischemic dilated cardiomyopathy. The main questions it aims to answer are:
- Are these repeated injections safe and well tolerated?
- Do they improve cardiac function and, if yes, to what extent?
详细描述
The overall objective of this study is to assess the safety and efficacy of repeated intravenous injections of the secretome of cardiovascular progenitor cells in severely symptomatic patients with drug-refractory left ventricular (LV) dysfunction secondary to non-ischemic dilated cardiomyopathy.
The rationale and design of this trial are based on three main assumptions:
- The tissue-repair capacity of transplanted cells can be duplicated by the delivery of the extracellular vesicles (EV) that they secrete.
- The greatest therapeutic efficacy seems to be achieved by using secreting cells that are committed to the same lineage as those of the tissue to be repaired, hence, the use of cardiovascular progenitor cells as the source of the EV-enriched secretome.
- Leveraging the benefits of cells, or their secreted products, by repeated administrations requires a non-invasive approach, which highlights the potential interest of the intravenous approach.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged between 18 to 80 years
- •Signed written informed consent
- •French Social Security affiliation;
- •Dilated cardiomyopathy defined by a dilated LV with a reduced EF ≤40% on echocardiography and/or CMR imaging, unexplained by pressure or volume overload (severe arterial hypertension or significant valve disease), coronary artery disease (as assessed by coronary angiography) or a systemic disease; in case of chemotherapy-induced cardiomyopathy, patients should have a period of at least two years of clinical cancer-free state* and a low estimated likelihood of recurrence (≤30% at 5 years), as determined by an oncologist, based on tumor type, response to therapy, and negative metastatic work-up at the time of diagnosis (*exceptions to this are carcinoma in situ or fully resected basal and squamous cell cancer of the skin);
- •NYHA Class III in spite of optimal heart failure maximally tolerated guideline-directed medical therapy, including cardiac resynchronization if needed, without other treatment options;
- •Plasma level of B-type natriuretic peptide (BNP) > 150 pg/mL or, N-terminal pro-BNP (NT-proBNP) ≥ 400 pg/mL;
- •For child-bearing aged women, efficient contraception such as combined (estrogen and progestogen containing) hormonal contraception or progestogen-only hormonal contraception associated with inhibition of ovulation and for men efficient contraception such as condom, during treatment and until the end of the relevant systemic exposure, i.e. until 3 months after the end of treatment.
排除标准
- •Implantation of a cardiac resynchronisation therapy device or an ICD unit during the preceding 3 months;
- •End-stage heart failure with reduced EF (HFrEF) defined as patients with American College of Cardiology Foundation/American Heart Association (ACCF/AHA) stage D (candidates for specialized interventions, including heart transplantation and mechanical assistance) or terminal HF (advanced HF with poor response to all forms of treatment, frequent hospitalizations and life expectancy < 12 months)
- •Patients treated with inotropic agents during the 1 month period prior to inclusion;
- •Acute heart failure (regardless of the cause);
- •Heart failure caused by cardiac valve disease, untreated hypertension or documented coronary artery disease with lesions which could explain the cardiomyopathy;
- •Cardiomyopathy due to a reversible cause e.g. endocrine disease, alcohol or drug abuse, myocarditis, Tako-Tsubo, or arrhythmias;
- •Cardiomyopathy due a syndromic/systemic disease (e.g. Duchenne's muscular dystrophy, immune/inflammatory/infiltrative disorders [amyloidosis, hemochromatosis]);
- •If post-chemotherapy cardiomyopathy: a history of radiation therapy AND evidence of constrictive physiology; a baseline computerized tomography scan or CMR showing new tumor or suspicious lymphadenopathy raising concern of malignancy; a trastuzumab treatment within the last 3 months;
- •Previous cardiac surgery;
- •Recent stroke (within the last 3 months);
- •Documented presence of a known LV thrombus, aortic dissection, or aortic aneurysm;
- •Uncontrolled ventricular tachycardia defined by sustained ventricular tachycardia, including electrical storm and incessant ventricular tachycardia with no response to antiarrhythmic medication; Internal Cardioverter Defibrillator firing in the 30 days prior to the first infusion;
- •History of drug-induced allergic reactions or allergy of any type having required treatment;
- •Contraindication to corticosteroids or anti-histaminic agents;
- •Contraindication to gadoterate meglumine if it will be used with CMR;
- •Hematological disease: anaemia (haematocrit < 25%), leukopenia (leucocytes < 2,500/μL) or thrombocytopenia (thrombocytes < 100,000/μL); myeloproliferative disorders, myelodysplastic syndrome, acute or chronic leukaemia, and plasma cell dyscrasias (multiple myeloma);
- •Coagulopathy not due to a reversible cause;
- •Diminished functional capacity for other reasons such as: Chronic Obstructive Pulmonary Disease (COPD) with Forced Expiratory Volume (FEV) <1 L/min, moderate to severe claudication or morbid obesity;
- •Diabetes with poorly controlled blood glucose levels and/or evidence of proliferative retinopathy;
- •Dialysis-dependent renal insufficiency;
- •Autoimmune disorders or current immunosuppressive therapy;
- •History of organ transplant or cell-based treatment;
- •Serum positivity for HIV, hepatitis BsAg, or viremic hepatitis C;
- •Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control;
- •Active infection;
- •Known allergy to aminoglycosides;
- •Patient under legal protection (guardianship);
- •Participation in another interventional trial;
- •Life expectancy less than one year.
- •Contraindication to 18FDG-PETscan
研究组 & 干预措施
Treated group
Experimental
A maximum of 12 patients will be included in the study following a dose-escalating design:
- Cohort 1 (4 patients) will receive 20x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 60x10E9 particles/kg;
- Cohort 2: in the absence of safety issues in Cohort 1, 8 patients will receive 40x10E9 particles/kg for each infusion, with a total of 3 infusions, for a cumulative dose of 120x10E9 particles/kg.
干预措施: Extracellular vesicle-enriched secretome of cardiovascular progenitor cells differentiated from induced pluripotent stem cells (Biological)
结局指标
主要结局
Serious Adverse Events
时间窗: 10 weeks after the onset of treatment: 6 weeks of treatment and 4 weeks of follow-up after the last IMP infusion.
Number of any potentially Serious Adverse Events (SAEs)/Reactions attributed to the experimental treatment: death (cardiovascular or of any cause), hospitalization for worsening heart failure, acute coronary syndrome (including myocardial infarction), sustained atrial and ventricular arrhythmias, ischemic stroke, immune-allergic or infectious reactions to the intravenous infusions of the IMP, and any other potential adverse effects detected and corroborated by clinical presentation, laboratory investigations and image analysis.
次要结局
- Validation of the bioactivity of the EV-enriched secretome by proliferation of human vascular endothelial cells.(12 months)
- Validation of the bioactivity of the EV-enriched secretome(12 months)
- Assessment of the effects of the IMP on immune and inflammatory responses at 3 weeks after the onset of the treatment.(3 weeks after the onset of the treatment.)
- Assessment of the effects of the IMP on immune and inflammatory responses at 10 weeks after the onset of the treatment.(10 weeks after the onset of the treatment.)
- Assessment of the effects of the IMP on immune and inflammatory responses at 6 weeks after the onset of the treatment.(6 weeks after the onset of the treatment.)
- Changes in LV function assessed by LV Volumes at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by LV volumes (ml/m2) by Cardiac Magnetic Resonance at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by LV ejection fraction at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by LV global longitudinal strain at 28 days after the end of the treatment.(28 days after the end of the treatment.)
- Changes in LV function assessed by the presence/extent of myocardial late-enhancement at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by Natriuretic peptide plasma levels at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Validation of the bioactivity of the EV-enriched secretome by activation of allogeneic peripheral blood mononuclear cells.(12 months)
- Changes in LV function assessed by Minnesota Living With Heart Failure questionnaire at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by LV ejection fraction at 28 days after the end of the treatment.(28 days after the end of the treatment.)
- Changes in LV function assessed by LV global longitudinal strain at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by LV global longitudinal strain at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by LV ejection fraction (%) by Cardiac Magnetic Resonance at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Assessment of the effects of the IMP on immune and inflammatory responses at 6 months after the last secretome infusion.(6 months after the last secretome infusion.)
- Changes in LV function assessed by NYHA at 28 days after the end of the treatment.(28 days after the end of the treatment.)
- Changes in LV function assessed by NYHA at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by NYHA at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by LV Volumes at 28 days after the end of the treatment.(28 days after the end of the treatment.)
- Changes in LV function assessed by LV Volumes at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Serious Adverse Events(12 months)
- Inflammatory response to IMP infusions(28 days, 6 and 12 months following the third infusion)
- Monitoring for Major Cardiovascular Adverse Events (MACE)(28 days following the last IMP infusion and subsequently until 1 year after the end of treatment)
- Changes in LV function assessed by Minnesota Living With Heart Failure questionnaire at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by LV ejection fraction at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by maximum oxygen consumption at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by Natriuretic peptide plasma levels at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by LV ejection fraction (%) by Cardiac Magnetic Resonance at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function Changes in LV function assessed by LV volumes (ml/m2) by Cardiac Magnetic Resonance at 12 months after the end of the treatment.(12 months after the end of the treatment.)
- Changes in LV function assessed by the presence/extent of myocardial late-enhancement at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by maximum oxygen consumption at 6 months after the end of the treatment.(6 months after the end of the treatment.)
- Changes in LV function assessed by Natriuretic peptide plasma levels at 28 days after the end of the treatment.(28 days after the end of the treatment.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory AnginaRefractory Angina PectorisAdvanced Coronary Heart DiseaseChronic Myocardial IschemiaNCT01508910Lisata Therapeutics, Inc.291
已完成
2 期
ACT34-CMI -- Adult Autologous CD34+ CellsMyocardial IschemiaNCT00300053Lisata Therapeutics, Inc.321
终止
2 期
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)Bladder CancerNCT01475266Nippon Kayaku Co., Ltd.51
已完成
2 期
ACP-01 in Patients With Critical Limb IschemiaCritical Limb IschemiaNCT02551679Hemostemix67
终止
3 期
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 DiabetesType 1 Diabetes MellitusNCT05018585Diamyd Medical AB321